Physician profile
Nikolas Steven Rademaker
NPI 1144996661
$3,030.14
in general payments reported to CMS, 2019-2025
42 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $178 · 2023: $113 · 2024: $751 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,751.72 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $343.97 | 2024-2025 | Imfinzi, Airsupra, Enhertu |
| Genzyme Corporation | $285.03 | 2024-2025 | |
| Janssen Biotech, INC. | $272.12 | 2022-2025 | Rybrevant, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $258.60 | 2024-2025 | |
| Pfizer INC. | $142.48 | 2024-2025 | |
| Abbvie INC. | $137.84 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.70 | 2024-2025 | Opdivo, Opdualag |
| Celgene Corporation | $95.97 | 2022-2025 | Reblozyl, Breyanzi |
| Seagen INC. | $93.33 | 2022-2023 | Adcetris |
| Incyte Corporation | $92.22 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Glaxosmithkline, LLC. | $79.36 | 2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $73.65 | 2024-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $61.89 | 2024-2025 | Iclusig |
| Axsome Therapeutics, INC. | $54.34 | 2025 | Auvelity |
| Verona Pharma, INC. | $53.89 | 2025 | Ohtuvayre |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $51.79 | 2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $51.41 | 2024-2025 | Keytruda, Keytruda Qlex, Reblozyl |
| Array Biopharma INC | $51.06 | 2025 | Mektovi, Xalkori, Braftovi |
| Genentech USA, INC. | $48.97 | 2025 | Itovebi, Tecentriq |
| Fennec Pharmaceuticals, INC. | $45.04 | 2024-2025 | Fyarro, Pedmark |
| Exelixis INC. | $44.73 | 2024-2025 | Cabometyx |
| Otsuka America Pharmaceutical, INC. | $43.90 | 2025 | Rexulti |
| Dendreon Pharmaceuticals LLC | $43.65 | 2024-2025 | Provenge |
| Kowa Pharmaceuticals America, INC. | $42.95 | 2024-2025 | Zoryve |
| Geron Corporation | $41.04 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $35.94 | 2024-2025 | |
| Octapharma USA, INC. | $32.17 | 2024 | Panzyga |
| Tersera Therapeutics LLC | $31.25 | 2025 | Quzyttir |
| Vanda Pharmaceuticals INC. | $28.88 | 2025 | Fanapt |
| Coherus Oncology, INC. | $26.66 | 2025 | Loqtorzi |
| Agios Pharmaceuticals, INC. | $26.66 | 2025 | Pyrukynd |
| Blueprint Medicines Corporation | $23.06 | 2024 | Ayvakit |
| Sumitomo Pharma America, INC. | $22.68 | 2025 | Gemtesa |
| Lilly USA, LLC | $22.53 | 2025 | Zepbound |
| Pharmaand Gmbh | $21.75 | 2025 | Rubraca |
| Lundbeck LLC | $19.46 | 2025 | Rexulti |
| Adc Therapeutics America, INC. | $19.44 | 2024 | |
| Ibsa Pharma INC. | $19.40 | 2025 | Licart, Flector, Tirosint |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.93 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $18.57 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.45 | 2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $13.38 | 2024 | Oxlumo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikolas Rademaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.